When does Sanofi report earnings and why does it matter for SAN.PA stock?

Sanofi reports on 28 Jan 2026. The release matters because management will update guidance, vaccine demand outlook and pipeline milestones that can move SAN.PA stock price and short‑term volatility.

What is Meyka AI's price forecast for SAN.PA stock?

Meyka AI's forecast model projects a yearly price of €86.14 versus the current €79.88, implying an upside of 7.83%. Forecasts are model projections and not guarantees.

What are key valuation metrics to watch for SAN.PA stock?

Watch PE at 15.24, EPS €5.24, price/ book 1.33, and free cash flow yield near 12.44%. Dividend per share is €3.92, giving a yield around 4.91% that supports total return assumptions.

What risks could pressure SAN.PA stock after earnings?

Main risks include weaker U.S. vaccine demand, lower Dupixent-related sales, clinical setbacks or regulatory delays, and any guidance cut. These would likely increase downside volatility for SAN.PA stock.

EU Stocks

SAN.PA Sanofi pre-market 27 Jan 2026: earnings ahead, amlitelimab momentum

ByHuzaifa Zahoor January 27, 2026January 27, 2026

SAN.PA stock opens pre-market on 27 Jan 2026 at €79.88 as investors position for Sanofi’s quarterly report due on 28 Jan 2026. The market will weigh revenue cadence, vaccine demand commentary and late‑stage data for amlitelimab. We summarise how pipeline news, valuation and dividends may move the share price and what to watch at the earnings call.